文献速递免疫规划传染病防控与疫情报告

2019-2021年菲律宾共和国和马来西亚同时暴发循环疫苗衍生脊髓灰质炎病毒1型和2型疫情

Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021.
PubMed 文献 · Vaccine · 2022-03-23

2019年9月菲律宾共和国确认同时暴发循环疫苗衍生脊髓灰质炎病毒1型和2型(cVDPV1、cVDPV2),马来西亚于2020年初确认。两国开展以单价Sabin株2型口服脊髓灰质炎疫苗(mOPV2)和双价口服脊髓灰质炎疫苗(bOPV)序贯补充免疫活动及增强监测的疫情应对。共检测到6例cVDPV1病例、13例cVDPV2病例和1例免疫缺陷相关疫苗衍生脊髓灰质炎病毒2型病例,环境监测污水采集点分离到35株cVDPV1和31株cVDPV2。自2020年3月以来两国未再检测到cVDPV1或cVDPV2。

要点

  • 菲律宾和马来西亚同时暴发cVDPV1和cVDPV2,两国特定地理区域存在持续人群流动。
  • 应对以mOPV2和bOPV序贯补充免疫活动及增强脊髓灰质炎病毒监测敏感性为主。
  • 共6例cVDPV1、13例cVDPV2和1例免疫缺陷相关疫苗衍生2型病例,环境分离35株cVDPV1和31株cVDPV2。

核心结论

  • 两国同时暴发cVDPV1和cVDPV2,应对面临挑战尤其受全球COVID-19大流行影响,自2020年3月以来未再检测到cVDPV1或cVDPV2。
  • 识别的重要经验可能对其他经历同时暴发cVDPV血清型疫情的国家有用。

研究设计与样本

  • 描述2019年9月菲律宾共和国确认cVDPV1和cVDPV2同时暴发、马来西亚于2020年初确认的疫情及两国应对工作。

主要发现

  • 共检测到6例cVDPV1病例、13例cVDPV2病例和1例免疫缺陷相关疫苗衍生脊髓灰质炎病毒2型病例。
  • 环境监测污水采集点分离到35株cVDPV1和31株cVDPV2。
  • 自2020年3月以来两国未再检测到cVDPV1或cVDPV2。
  • 两国应对工作面临挑战,尤其由全球COVID-19大流行引起。

临床怎么用

  • 疫情应对聚焦于以mOPV2和bOPV序贯补充免疫活动以及增强脊髓灰质炎病毒监测敏感性的活动。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concurrent outbreaks of circulating vaccine-derived poliovirus serotypes 1 and 2 (cVDPV1, cVDPV2) were confirmed in the Republic of the Philippines in September 2019 and were subsequently confirmed in Malaysia by early 2020. There is continuous population subgroup movement in specific geographies between the two countries. Outbreak response efforts focused on sequential supplemental immunization activities with monovalent Sabin strain oral poliovirus vaccine type 2 (mOPV2) and bivalent oral poliovirus vaccines (bOPV, containing Sabin strain types 1 and 3) as well as activities to enhance poliovirus surveillance sensitivity to detect virus circulation. A total of six cVDPV1 cases, 13 cVDPV2 cases, and one immunodeficiency-associated vaccine-derived poliovirus type 2 case were detected, and there were 35 cVDPV1 and 31 cVDPV2 isolates from environmental surveillance sewage collection sites. No further cVDPV1 or cVDPV2 have been detected in either country since March 2020. Response efforts in both countries encountered challenges, particularly those caused by the global COVID-19 pandemic. Important lessons were identified and could be useful for other countries that experience outbreaks of concurrent cVDPV serotypes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Snider CJ, Boualam L, Tallis G, et al. Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019-2021. Vaccine. 2022. PMID: 35337673. doi:10.1016/j.vaccine.2022.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。